The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Blood-brain barrier drug targeting: the future of brain drug development.
Abstract
As human longevity increases, the likelihood of the onset of diseases of the brain (and other organs) also increases. Clinical therapeutics offer useful long-term treatments, if not cures, if drugs can be delivered appropriately and effectively. Unfortunately, research in drug transport to the brain has not advanced very far. Through better characterization of the transport systems utilized within the blood-brain barrier, a greater understanding of how to exploit these systems will lead to effective treatments for brain disorders. Pardridge reviews the functions of the various known transport systems in the brain and discusses how the development of BBB drug-targeting programs in pharmaceutical and academic settings may lead to more efficacious treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The blood-brain barrier (BBB) is a strictly modulated interface between the peripheral circulation and the central nervous system (CNS).
“The blood-brain barrier (BBB) is a strictly modulated interface between the peripheral circulation and the central nervous system (CNS) (Pardridge, 2003).”
From Acute Cerebral Ischemia Increases a Set of Brain-Specific miRNAs in Serum Small Extracellular Vesicles (2022) · cites this paper as Pardridge, 2003
Citations
Cites
Farrell, C. L., & Pardridge, W. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5779 · Cited by 314
Self-citationLi, J. Y., Boado, R. J., & Pardridge, W. M. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200101000-00008 · Cited by 164
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
Campisi, M., Shin, Y., Osaki, T., Hajal, C., Chiono, V., & Kamm, R. D. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.014 · Cited by 718
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715
The blood-brain barrier: an engineering perspective
Wong, A. D., Ye, M., Levy, A. F., Rothstein, J. D., Bergles, D. E., & Searson, P. C. (2013) · Frontiers in Neuroengineering · doi:10.3389/fneng.2013.00007 · Cited by 662
Solid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506
Strategy for effective brain drug delivery
Alam, M. I., Beg, S., Samad, A., Baboota, S., Kohli, K., Ali, J., Ahuja, A., & Akbar, M. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.05.003 · Cited by 415
Current Strategies to Enhance Delivery of Drugs across the Blood–Brain Barrier
Teleanu, R. I., Preda, M. D., Niculescu, A.-G., Vladâcenco, O., Radu, C. I., Grumezescu, A. M., & Teleanu, D. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050987 · Cited by 200
CNS Drug Delivery Systems: Novel Approaches
Pathan, S., Iqbal, Z., Zaidi, S., Talegaonkar, S., Vohra, D., Jain, G., Azeem, A., Jain, N., Lalani, J., Khar, R., et al. (2009) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221109787158355 · Cited by 193
Abbott, N. J. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.014 · Cited by 181
Stem Cell-Based Human Blood–Brain Barrier Models for Drug Discovery and Delivery
Aday, S., Cecchelli, R., Hallier-Vanuxeem, D., Dehouck, M. P., & Ferreira, L. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.01.001 · Cited by 169
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Ribecco-Lutkiewicz, M., Sodja, C., Haukenfrers, J., Haqqani, A. S., Ly, D., Zachar, P., Baumann, E., Ball, M., Huang, J., Rukhlova, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19522-8 · Cited by 148
Calias, P., Papisov, M., Pan, J., Savioli, N., Belov, V., Huang, Y., Lotterhand, J., Alessandrini, M., Liu, N., Fischman, A. J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030341 · Cited by 133
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Rodrigues, R. O., Shin, S.-R., & Bañobre-López, M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02720-0 · Cited by 44
Short Peptide-Mediated Brain-Targeted Drug Delivery with Enhanced Immunocompatibility
Guan, J., Jiang, Z., Wang, M., Liu, Y., Liu, J., Yang, Y., Ding, T., Lu, W., Gao, C., Qian, J., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01216 · Cited by 34
Zhou, X., Xu, C., Chao, D., Chen, Z., Li, S., Shi, M., Pei, Y., Dai, Y., Ji, J., Ji, Y., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.874903 · Cited by 13
Metadata
- Authors
- Pardridge, W. M.
- Venue
- Molecular Interventions
- Publisher
- CLOCKSS Archive
- Published
- 2003-03-01
- Volume
- 3
- Issue
- 2
- Pages
- 90-105
- ISSN
- 1534-0384
- Cited by
- 570
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
